The report forecasts the global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021.
The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
According to the report, one of the major drivers for this market is increased demand for mAbs. Monoclonal antibodies represent a major segment of the global protein therapeutics market. The understanding of diseases at the molecular level increases the development and use of mAbs in their treatment. These antibodies have a high affinity toward specific disease cells and areas that need to be treated. There is a remarkable increase in the use of mAbs in various therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy.
- F. Hoffmann-La Roche
- Johnson & Johnson
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Market segmentation by product type
Part 07: Market segmentation by therapy area
Part 08: Market segmentation by protein function
Part 09: Geographical segmentation
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/3294gp/global_protein